Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:06:37.482Z.
Calculation as of: 2026-10-06T17:06:37.482Z.
Quote observation: 2026-10-06T17:05:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f06204e81c8a2ed41a5798160e844c591f5150b644efe168084329023db9ebc4
PE RATIO
N/A
Market Cap
$440.82M
PE Ratio
N/A
TTM Avg
139.84
3Y Avg
139.84
5Y Avg
139.84
Market Cap
$435.58M
PE Ratio
39.96
TTM Avg
54.06
3Y Avg
54.06
5Y Avg
54.06
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | $448.58M | N/A | N/A | N/A | N/A |
| Ovid Therapeutics Inc. (OVID)vs › | $446.63M | N/A | 2.09 | 2.09 | 2.09 |
| NeuroPace, Inc. (NPCE)vs › | $444.41M | N/A | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $440.82M | N/A | 139.84 | 139.84 | 139.84 |
| NRC Health (NRC)vs › | $459.97M | 80.86 | 41.70 | 28.27 | 29.07 |
| Assembly Biosciences, Inc. (ASMB)vs › | $435.58M | 39.96 | 54.06 | 54.06 | 54.06 |
| Editas Medicine, Inc. (EDIT)vs › | $433.53M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $433.73M | N/A | 138.05 | 184.03 | 168.06 |
| Sight Sciences, Inc. (SGHT)vs › | $468.08M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $471.02M | N/A | 16.90 | 16.90 | 16.90 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$8.32
Forward EPS (Est.)
$-0.77
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
